Carbonyl-substituted diazaspiro compounds and uses thereof

By blocking the interaction between menin and MLL and MLL fusion proteins through carbonyl-substituted diazaspiro compounds, the problem of difficulty in controlling the pathogenesis of MLL rearrangement leukemia in existing technologies is solved, providing an effective means to treat MLL rearrangement leukemia and NPM1 mutant AML.

CN122404346APending Publication Date: 2026-07-17LES LAB SERVIER SA
View PDF 1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
LES LAB SERVIER SA
Filing Date
2022-12-02
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively inhibit the interaction between menin and MLL and MLL fusion proteins, making it difficult to control the pathogenesis of MLL rearrangement leukemia, especially in infantile acute leukemia and NPM1-mutant AML with poor treatment outcomes.

Method used

A carbonyl-substituted diazaspiro compound was provided, which, by interacting with menin, blocked the interaction of menin with MLL and MLL fusion proteins, thereby inhibiting their function.

Benefits of technology

Effectively inhibiting the interaction between menin and MLL and MLL fusion proteins has potential therapeutic value for MLL rearrangement leukemia and NPM1-mutant AML.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122404346A_ABST
    Figure CN122404346A_ABST
Patent Text Reader

Abstract

本公开涉及式I的化合物，其中变量如说明书中所定义；含有它们的药物组合物、制备它们的方法和它们的用途。(I)。
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Inhibitors of the menin-MLL interaction

    WO2017214367A1